| (USD) | Mar 2026 | Y/Y change |
|---|---|---|
| Revenue | 273.60M | — |
| Operating expense | — | — |
| Net income | 28.00M | — |
| Net profit margin | — | — |
| Earnings per share | — | — |
| EBITDA | — | — |
| Effective tax rate | — | — |
Over the past year, STVN returned +0.3% with dividends reinvested.
| Period | Total return |
|---|---|
| YTD | +12.7% |
| 1 year | +0.3% |
| 5 years | -7.3% |
| All-time high | $33.15 (Feb 2024) |
Returns are total returns and include reinvested dividends. The all-time high is the highest monthly closing price on record.
See what $1,000 in STVN would be worth today ›Yes. Stevanato Group S.p.A. paid 1 dividend over the past 12 months. The most recent was $0.06 per share on Jun 11, 2026. The dividend yield is 0.27%.
Stevanato Group S.p.A. stock trades on NYSE under the ticker symbol STVN.
Stevanato Group S.p.A. is part of the Healthcare sector.
Stevanato Group S.p.A. has a market cap of 6.17B USD, based on the latest quote.
Stevanato Group S.p.A. is expected to report earnings around Nov 5, 2026. That date is an estimate and has not been confirmed by the company.
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug products, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
